Please try another search
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Name | Age | Since | Title |
---|---|---|---|
Jeremy Max Levin | 68 | 2020 | Chairperson |
Lawrence B. Gozlan | 44 | 2020 | Independent Non-Executive Director |
Tim Jackson | - | - | Member of Clinical Advisory Board |
Julia A. Haller | 68 | 2021 | Independent Non-Executive Director |
Jason Scott Slakter | 65 | - | Member of Clinical Advisory Board |
Charles C. Wykoff | - | - | Member of Clinical Advisory Board |
Megan Baldwin | 49 | 2014 | Founder, Chief Innovation Officer & Executive Director |
Quinton C. Oswald | 73 | 2022 | Independence Non-Executive Director |
Susan C. Orr | 61 | 2022 | Independent Non-Executive Director |
Sujal A. Shah | 51 | 2024 | Non-Executive Director |
Anshul Thakral | 46 | 2023 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review